The recent discovery of compounds that target the translation termination factor eRF1 for proteasomal degradation offers a new avenue for the development of drugs to treat genetic diseases caused by nonsense mutations.
You can consent to the use of such technologies by closing this notice.
Customise your preferences for any tracking technology
The following allows you to customize your consent preferences for any tracking technology used
to help us achieve the features and activities described below. To learn more about how these trackers help us
The Nature Portfolio Health Community provides a forum for all those interested in health and disease research to share the latest discoveries, news, and opinions; from disease modelling through to digital medicine approaches.